Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

MicroStrategy Inc. (NASDAQ:MSTR) has officially rebranded as Strategy, reflecting its sharpened focus on Bitcoin (CRYPTO: BTC ...

Strategy (formerly MicroStrategy) reported a $1.016 billion Q4 2024 loss, largely due to Bitcoin impairment charges.

Bitcoin play MicroStrategy announced a rebrand and new company name ahead of its Q4 earnings miss late Wednesday. The software services provider and corporate bitcoin treasury has been on a ...